Home › Urothelial (Transitional Cell) Carcinoma › NCT05874921

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

RecruitingObservational study

uTRACT Jelmyto Registry: A Multicenter, Prospective and Retrospective Registry to Evaluate Real World Experience and Outcomes of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Who can join

Ages 18 and older · All sexes

Full eligibility criteria

Inclusion Criteria:

* Adults \>18 years old and capable of giving informed consent.
* Diagnosis of UTUC.
* Receipt of at least 1 dose of JELMYTO after FDA approval (15 Apr 2020).

Exclusion Criteria:

* Incapable of giving informed consent (e.g., incarcerated individuals, individuals with dementia).
* Receipt of 1 or more doses of JELMYTO (also referred to as UGN-101 or Mitogel in clinical development) before FDA approval (on or before 15 Apr 2020).
* Pregnancy or lactation.
* Unable to comply with protocol requirements (for prospective data capture).
* Any medical or mental condition(s) that makes participation in the Registry inadvisable in the opinion of the Investigator (for prospective data capture).

About the study

The purpose of this registry is to evaluate real world experience and outcomes of patients with Upper Tract Urothelial Cancer (UTUC) treated with Jelmyto in the United States.

What is being tested

Jelmyto (mitomycin) for pyelocalyceal solution (drug)

Sponsor: UroGen Pharma Ltd. · Participants: 450 · Started: Nov 17, 2023

Contact the study team

Michael Louie, MD, MPH, MSc · Phone: 855-987-6436

Official record on ClinicalTrials.gov — NCT05874921

Locations in the U.S.

California	Providence St. Johns Health Center, Santa Monica
Florida	University of Florida, Gainesville Mount Sinai Medical Center of Florida, Inc., Miami H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., Tampa
Illinois	Northwestern University, Chicago
Indiana	Indiana University, Indianapolis
Iowa	The State University of Iowa, Iowa City
Maryland	Chesapeake Urology, Baltimore Johns Hopkins Medical Center, Baltimore
Massachusetts	Brigham and Women's Hospital, Boston Mass General Brigham, Boston
Michigan	University of Michigan, Ann Arbor
Missouri	University of Missouri, Columbia
New Jersey	Rutgers, New Brunswick
New York	The Feinstein Institutes for Medical Research, Lake Success NYU Grossman School of Medicine, New York SUNY Upstate, Syracuse
North Carolina	The University of North Carolina Chapel Hill, Chapel Hill
Ohio	Ohio State University, Columbus
Tennessee	Vanderbilt University Medical Center, Nashville
Texas	UT Southwestern Medical Center, Dallas The University of Texas M.D. Anderson Cancer Center, Houston

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.